COMMUNIQUÉS West-GlobeNewswire

FemPulse Pivotal Study Selected For Presentation at the American Urological Association Annual Conference
04/03/2026
SAN FRANCISCO, March 04, 2026 (GLOBE NEWSWIRE) -- FemPulse™, a bioelectronic medical technology company with first application overactive bladder (OAB), announced today that the Company’s pivotal clinical study was [...]
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
04/03/2026
RAMAT GAN, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) (“Can-Fite” or the “Company”), a biotechnology company advancing a pipeline of proprietary small-molecule [...]
Baylor Genetics to Highlight New Data and Product Innovations at 2026 ACMG Annual Clinical Genetics Meeting
04/03/2026
Company’s exhibit theater presentation will highlight multiomic and multimodal innovations in rare disease diagnostics HOUSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Baylor Genetics , a leading diagnostic genomics partner [...]
Koç University Hospital, a Koç Healthcare Institution, is Named Türkiye’s Top Hospital and Ranked Among the Newsweek–Statista World’s Best Hospitals 2026
04/03/2026
ISTANBUL, March 04, 2026 (GLOBE NEWSWIRE) -- Koç University Hospital a leading institution of Koç Healthcare has set the national benchmark for excellence in healthcare. In the recently announced 2026 edition of [...]
Achieve Life Sciences Presents Data at SRNT Demonstrating Successful Cessation in Smokers with Extensive Prior Treatment Exposure; and on Participant Experience in the ORCA-OL Study
04/03/2026
A pooled Phase 3 analysis of more than 1,600 people who smoke showed high quit rates; including among those who had previously not succeeded with other smoking cessation medications and regardless of the number of prior [...]
BioRestorative Therapies, Inc. Issues Letter to Shareholders Highlighting Major Milestones, Regulatory Alignment, Clinical Execution and Capital Strategy
04/03/2026
Company is well positioned following positive FDA Type B meeting outcome, fully enrolled Phase 2 trial for its lead clinical program, and recent $5 million public offering, as commercial operation continues to build [...]
Elutia Regains Compliance with Nasdaq Listing Requirements
04/03/2026
GAITHERSBURG, Md., March 04, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it has received notice from Nasdaq [...]
Ardelyx to Participate in Upcoming Investor Conferences
04/03/2026
WALTHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical [...]
Vericel Announces FDA Approval of New State-of-the-Art Advanced Therapy Manufacturing Facility
04/03/2026
Company Achieves Significant Regulatory and Operational Milestone Substantially Increases Manufacturing Capacity to Support Long-Term Growth Enables Potential MACI Commercialization Outside of the U.S. CAMBRIDGE, Mass [...]
Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference
04/03/2026
BRISBANE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, [...]
Genvor Announces Strategic Expansion into Health and Wellness Market, Leveraging Proprietary AI-Accelerated BioCypher Platform to Develop Consumer Peptide Solutions
04/03/2026
Company’s proprietary peptide platform expands beyond agriculture into human recovery, performance, and wellness Woodland, CA, March 04, 2026 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCQB: GNVR), a biotechnology company [...]
Galecto Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/03/2026
BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company working to redefine care for people with hematologic disorders, today announced that it granted equity awards on March 2, [...]
CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026
04/03/2026
SOUTH SAN FRANCISCO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report full year [...]
ICAN Poll: Overwhelming Majority of Respondents Oppose Glyphosate Stockpiling, Reject Manufacturer Immunity
04/03/2026
New public opinion data from 2,569 respondents reveals near-unanimous opposition to key provisions of the administration’s glyphosate executive order AUSTIN, Texas, March 04, 2026 (GLOBE NEWSWIRE) -- The Informed [...]
AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million
04/03/2026
OCALA, Fla., March 04, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead [...]
Autonomix Medical Selected as Top Abstract at CRT 2026 and Selected for Podium Presentation of Clinical Feasibility and Outcomes of Novel Technique for Transvascular Peripheral RF Nerve Neurolysis
04/03/2026
THE WOODLANDS, TX, March 04, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today [...]
MannKind to Participate in Upcoming Investor Conferences
04/03/2026
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , announced today its attendance at two upcoming investor conferences, at which MannKind’s Chief [...]
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis
04/03/2026
Phase 3 study designed with total hip BMD primary endpoint assessed at 12 months, rather than at 24 months EB613 single tablet final commercial formulation (Next-Gen EB613) replaces multi-tablet EB613 as Phase 3 [...]
Standard Process® Launches Canine Cognition Support to Help Aging Dogs Maintain Brain Health
04/03/2026
New Veterinary Formulas™ supplement supports alertness and awareness with clinically researched ingredients PALMYRA, Wis., March 04, 2026 (GLOBE NEWSWIRE) -- Standard Process ® , a pioneer in whole food-based [...]

Pages